US2021009689A1PendingUtilityA1

Methods and compositions for inhibiting cd32b expressing cells

Assignee: XENCOR INCPriority: May 30, 2007Filed: Sep 23, 2020Published: Jan 14, 2021
Est. expiryMay 30, 2027(~0.8 yrs left)· nominal 20-yr term from priority
C07K 16/00C07K 16/2851C07K 2317/734C07K 2317/52C07K 2317/72C07K 2317/53C07K 16/2878C07K 2317/524C07K 2317/92C07K 2317/24A61P 3/10A61P 19/02C07K 2317/31C07K 2317/71C07K 2317/77C07K 16/283C07K 2317/732A61P 35/00C07K 16/2803A61K 2039/505A61P 29/00A61P 1/00C07K 2317/73A61P 37/06A61P 37/08C07K 2317/76
78
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to immunoglobulins that bind FcγRIIb+ cells and coengage the antigen on the cell's surface and an FcγRIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins.

Claims

exact text as granted — not AI-modified
We claim: 
     
         1 . A nucleic acid encoding an Fc variant comprising at least amino acid modifications G236N and S267E as compared to a parent Fc polypeptide, wherein numbering is according to the EU index according to Kabat. 
     
     
         2 . An expression vector comprising the nucleic acid of  claim 1 . 
     
     
         3 . A host cell comprising the vector of  claim 2 . 
     
     
         4 . A nucleic acid encoding a heavy chain of an antibody, the heavy chain comprising an Fc variant comprising at least amino acid modifications G236N and S267E as compared to a parent Fc polypeptide, wherein numbering is according to the EU index according to Kabat. 
     
     
         5 . An expression vector comprising the nucleic acid of  claim 4 . 
     
     
         6 . A host cell comprising the vector of  claim 5 .

Join the waitlist — get patent alerts

Track US2021009689A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.